ArticleFrontiers in oncology2023

Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1.

Rongbin Qi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.